Foghorn Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 116
- Market Cap
- $439.8M
- Introduction
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04965753
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Miami Health System, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
- Conditions
- Relapsed Chronic Myelomonocytic LeukemiaAdvanced Hematologic MalignancyRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04891757
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
FHD-286 in Subjects With Metastatic Uveal Melanoma
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Foghorn Therapeutics Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT04879017
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States